Welcome to our dedicated page for Helius Med Technologies news (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Helius Med Technologies stock.
Overview
Helius Medical Technologies Inc (Nasdaq: HSDT) is a specialized neurotechnology company dedicated to addressing neurological deficits through innovative, non-invasive solutions. With a core focus on neuromodulation and neurostimulation, Helius leverages its proprietary technology to promote neuroplasticity—the brain's capacity to adapt and rewire—in order to improve gait, balance, and motor functions in individuals affected by neurological trauma and disease.
Core Technology and Therapeutic Approach
The company’s flagship product, the Portable Neuromodulation Stimulator (PoNS), is a medical device that delivers mild electrical impulses via a tongue-placed mouthpiece. This unique mode of delivery is designed to activate cranial nerves and stimulate neural pathways, facilitating physiologic compensatory mechanisms. The therapeutic approach is used primarily in conjunction with supervised rehabilitation, merging physical therapy with targeted neuromodulation to restore lost function and improve overall mobility in patients coping with conditions such as multiple sclerosis, mild-to-moderate traumatic brain injury, and stroke-induced gait deficits.
Clinical Applications and Market Position
Helius Medical Technologies stands at the intersection of advanced clinical neuroscience and practical medical technology. Its technology is underpinned by robust clinical research and regulatory milestones, demonstrating significant improvements in balance and gait through measurable neuroplastic changes. The company has navigated complex reimbursement landscapes and regulatory frameworks in key markets, ensuring that its therapeutic solutions are accessible for patient populations in both Canada and the United States.
Business Model and Revenue Generation
Helius employs a multifaceted business model focused on development, licensing, and strategic acquisitions. Revenue generation primarily stems from the commercialization of its PoNS device, which is integrated within existing medical and therapeutic frameworks. The company’s approach involves building partnerships with federal healthcare systems, such as the Veterans Administration, and negotiating reimbursement arrangements with third-party payers. This model aligns technical innovation with market access initiatives, targeting a well-defined niche in the neurological rehabilitation market.
Strategic Collaborations and Industry Impact
Through strategic collaborations with clinical research centers and governmental contracting entities, Helius Medical Technologies has established critical validation of its technology with real-world applications. The integration of PoNS into prominent clinical trials and its inclusion on federal supply schedules underscore the company’s commitment to addressing unmet patient needs in neurorehabilitation. Moreover, its work in achieving reimbursement from major insurers further solidifies its role as a pivotal player in the neurotechnology space.
Research, Development, and Regulatory Engagement
The company has consistently demonstrated its commitment to research and development, investing significantly in studies that underscore its technology’s efficacy. Ongoing clinical registrational programs including those focused on stroke recovery exemplify the company’s dedication to gathering comprehensive clinical data. Regulatory engagement continues to be a cornerstone of its strategy as it works closely with agencies to secure approvals and reimbursement adjustments, which are essential for widespread clinical adoption.
Market Significance and Competitive Landscape
Operating in the highly specialized field of neurotechnology, Helius Medical Technologies distinguishes itself by targeting therapeutics that facilitate neuroplasticity—a key differentiator that underpins its market positioning. By addressing critical symptoms associated with neurological impairments through a non-invasive, easily accessible device, Helius satisfies a crucial need within the broader healthcare ecosystem. Its competitive edge is maintained through continuous research, strategic partnerships, and a clear focus on providing tangible improvements in patient mobility and quality of life.
Conclusion
Helius Medical Technologies Inc embodies innovation in neurotech, blending advanced scientific concepts with practical applications to offer a transformative therapeutic modality for patients suffering from neurological deficits. The company’s dedication to neuromodulation through its PoNS device, comprehensive clinical validation, and proactive engagement with regulatory bodies collectively establish it as a noteworthy entity in the field of medical devices and neurological rehabilitation.
Helius Medical Technologies (HSDT) reported a strong Q3 2022 with total revenue soaring by 80% to $196,000 compared to $109,000 in Q3 2021. This is attributed to the commercial availability of PoNS Therapy, which has gained positive market traction. The company raised $18 million in a public offering, providing $16.7 million in cash reserves for operations through 2023. Operating loss increased to $4.9 million, but net loss improved to $1 million from $4.7 million year-over-year, indicating a shift towards operational stability.
Helius Medical Technologies, Inc. (Nasdaq:HSDT) has announced the addition of the MGH Institute of Health Professions as the fourth Center of Excellence in its Therapeutic Experience Program (TEP). This multi-center, open-label observational trial aims to assess the adherence to Portable Neuromodulation Stimulator (PoNS) therapy among multiple sclerosis (MS) patients. Enrollment is expected to start in Q4 2022, involving 50-60 participants across 10-12 centers. The study seeks to evaluate the relationship between treatment adherence and gait improvement in MS.
Helius Medical Technologies (Nasdaq: HSDT) announced the addition of Oregon Health & Science University to its Therapeutic Experience Program, aiming to evaluate the effects of PoNS therapy for gait improvement in patients with multiple sclerosis (MS). The study is a multi-center, open-label trial to assess adherence to the PoNS device combined with physical therapy. Enrollment is expected to start in Q4 2022, targeting 50-60 MS patients across 10-12 Centers of Excellence in the U.S. Key endpoints include maintenance of gait improvement and overall functional outcomes.
Helius Medical Technologies will showcase its innovative Portable Neuromodulation Stimulator (PoNS®) at the ACRM Conference in Chicago from November 8-11. Visitors to booth 512 can explore how PoNS aids those with multiple sclerosis (MS) in improving gait deficiencies. The device uses electrical impulses through the tongue to stimulate neural pathways, enhancing mobility. Physical therapists can register for free online training to maximize the effectiveness of PoNS therapy. Helius is committed to supporting MS patients as 70% report mobility challenges.
Helius Medical Technologies (NASDAQ: HSDT) will release its Q3 2022 financial results on November 14, 2022, before the market opens. Following this, CEO Dane C. Andreeff and CFO Jeffrey S. Mathiesen will host a conference call at 8:30 a.m. ET to discuss the results and provide insights into the commercialization of PoNS®. The call can be accessed via registration, and a webcast will be archived for later viewing on the company’s investor relations website.
Helius Medical Technologies emphasizes its gratitude towards physical therapists skilled in using the Portable Neuromodulation Stimulator (PoNS®) during National Physical Therapy Month. The company aims to expand online training for therapists to enhance treatment for individuals with multiple sclerosis (MS). Clinical trials show that PoNS therapy significantly improves gait, with 58.3% of MS patients achieving notable gait enhancement. Helius is fostering a growing community of trained professionals to further support MS patients' mobility and quality of life.
Helius Medical Technologies (Nasdaq:HSDT) announced that its executives, Dane Andreeff and Jeff Mathiesen, will present at the ROTH Capital Partners Inaugural Healthcare Opportunities Conference on October 6, 2022, at 8:45 AM ET in New York City. Attendees can arrange 1-on-1 meetings with management through Roth Capital. Helius focuses on neurological wellness and offers the Portable Neuromodulation Stimulator (PoNS®), a device that aids in treating gait deficits associated with multiple sclerosis and traumatic brain injuries. For more information, visit their website.
Helius Medical Technologies (HSDT) announced the approval of an equity award under its 2021 Inducement Plan, as a material inducement for a new employee effective September 13, 2022. The award comprises an option to purchase 10,000 shares at an exercise price of $0.54 per share, matching the closing price on the grant date. The option vests over four years, with 25% vesting annually. Helius is focused on neurological wellness and has developed the Portable Neuromodulation Stimulator (PoNS), aimed at treating gait deficits from conditions like multiple sclerosis.
Helius Medical Technologies, Inc. (Nasdaq:HSDT) announced that its executives will present at two healthcare conferences this September. The first is the H.C. Wainwright 24th Annual Global Investment Conference (September 12-14, 2022), available on demand. The second is the Ladenburg Thalmann Healthcare Conference in New York City on September 29, 2022, at 10:00 AM ET. Helius focuses on neurological wellness and offers the Portable Neuromodulation Stimulator (PoNS), a non-surgical device aimed at improving balance and gait for patients with multiple sclerosis and traumatic brain injury.
Helius Medical Technologies, Inc. (Nasdaq:HSDT) reported Q2 2022 financial results with revenues increasing by 68% to $119K, primarily from PoNS Therapy sales for MS patients. The company initiated U.S. commercial sales and launched a Patient Therapy Access Program to improve accessibility. Operating expenses decreased to $3.5M, leading to a reduced net loss of $3.8M compared to $6.0M in Q2 2021. Cash reserves total $19.7M post-recent financing, expected to fund operations through 2023. The company anticipates modest revenue growth for Q3, driven by continued sales coverage and patient pairing efforts.
FAQ
What is the current stock price of Helius Med Technologies (HSDT)?
What is the market cap of Helius Med Technologies (HSDT)?
What is the core focus of Helius Medical Technologies Inc?
What conditions does the PoNS device target?
How does the PoNS device work?
What is the significance of neuroplasticity in Helius' treatment approach?
How does Helius generate revenue?
What makes Helius competitive in the neurotechnology space?
What role do research and clinical trials play for the company?
How is Helius engaging with regulatory bodies?
